Literature DB >> 33307962

HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway.

Jianxin Xu1, Xuejiao Fang1, Luye Long1, Sixuan Wang1, Shihan Qian1, Jianxin Lyu1.   

Abstract

BACKGROUND: Breast cancer is the most common cancer in women, and triple-negative breast cancer (TNBC) accounts for about 15-20% of all breast cancer. High mobility group AT-hook 2 (HMGA2) is overexpressed in some tumors and closely associated with patients' prognosis. However, the mechanisms involved in the regulation of HMGA2 in TNBC still remain unclear.
METHODS: In this study, HMGA2 level in TNBC cell lines was analyzed by western blot. After knockdown of HMGA2 expression by RNA interference in TNBC cell lines MDA-MB-231 and SUM149, wound healing and transwell assays were conducted to examine the effects of HMGA2 on migration and invasion. Tumor metastasis was assessed in amouse xenograft model invivo. Furthermore, expression levels of epithelial-mesenchymal transition (EMT) biomarkers and involvement of the Hippo-YAP pathway were detected by western blot.
RESULTS: Compared to normal breast epithelial cells, the expression levels of HMGA2 were significantly increased in TNBC cell lines (all P< .05). Downregulation of HMGA2 dramatically inhibited the migration and invasion of MDA-MB-231 and SUM149 cells (all P< .01) invitro, and suppressed the tumor metastasis of nude mice xenograft model invivo. Western blot analysis revealed alterations in EMT biomarkers: the expression of mesenchymal markers N-cadherin, Vimentin and Snail were decreased, while the expression of epithelial marker E-cadherin was increased. Downregulated expression of HMGA2 attenuated Hippo-YAP related protein expression and the stability of YAP.
CONCLUSIONS: HMGA2 is highly expressed in TNBC cells. Downregulation of HMGA2 inhibits the migration and invasion of TNBC and invivo tumor metastasis mediated through inhibition of EMT and Hippo-YAP pathway.

Entities:  

Keywords:  EMT; HMGA2; Hippo-YAP signaling pathway; Invasion and migration; TNBC

Mesh:

Substances:

Year:  2020        PMID: 33307962      PMCID: PMC7834087          DOI: 10.1080/15384047.2020.1832429

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  44 in total

1.  Action of actinomycin D on animal cells and viruses.

Authors:  E REICH; R M FRANKLIN; A J SHATKIN
Journal:  Proc Natl Acad Sci U S A       Date:  1962-07-15       Impact factor: 11.205

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  KRAS and YAP1 converge to regulate EMT and tumor survival.

Authors:  Diane D Shao; Wen Xue; Elsa B Krall; Arjun Bhutkar; Federica Piccioni; Xiaoxing Wang; Anna C Schinzel; Sabina Sood; Joseph Rosenbluh; Jong W Kim; Yaara Zwang; Thomas M Roberts; David E Root; Tyler Jacks; William C Hahn
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

4.  Silencing of HMGA2 promotes apoptosis and inhibits migration and invasion of prostate cancer cells.

Authors:  Zhan Shi; Ding Wu; Run Tang; Xiang Li; Renfu Chen; Song Xue; Chengjing Zhang; Xiaoqing Sun
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

5.  Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product.

Authors:  M Sudol
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

6.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 7.  The HMGA proteins: a myriad of functions (Review).

Authors:  Isabelle Cleynen; Wim J M Van de Ven
Journal:  Int J Oncol       Date:  2008-02       Impact factor: 5.650

8.  Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.

Authors:  Kazuo Motoyama; Hiroshi Inoue; Yoshito Nakamura; Hiroyuki Uetake; Kenichi Sugihara; Masaki Mori
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

Review 10.  High mobility group a proteins as tumor markers.

Authors:  Pierlorenzo Pallante; Romina Sepe; Francesca Puca; Alfredo Fusco
Journal:  Front Med (Lausanne)       Date:  2015-03-25
View more
  4 in total

Review 1.  The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.

Authors:  Ioanna Akrida; Vasiliki Bravou; Helen Papadaki
Journal:  Mol Biol Rep       Date:  2022-05-23       Impact factor: 2.742

Review 2.  HMGA2 as a Critical Regulator in Cancer Development.

Authors:  Behzad Mansoori; Ali Mohammadi; Henrik J Ditzel; Pascal H G Duijf; Vahid Khaze; Morten F Gjerstorff; Behzad Baradaran
Journal:  Genes (Basel)       Date:  2021-02-13       Impact factor: 4.096

Review 3.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

4.  Knockdown circTRIM28 enhances tamoxifen sensitivity via the miR-409-3p/HMGA2 axis in breast cancer.

Authors:  Shiyong Yang; Changwu Zou; Yuxin Li; Xianguo Yang; Wei Liu; Guannan Zhang; Nina Lu
Journal:  Reprod Biol Endocrinol       Date:  2022-09-30       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.